Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATAI Life Sciences
Biotech
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
Atai announces CEO transition plans. Lilly's Alonzo Weems will retire after 27 years. Novartis China President set to lead all ex-US commercial work.
Max Bayer
,
Gabrielle Masson
May 17, 2024 8:30am
2 months after depression fail, Atai lays off 30% of staff
Mar 6, 2023 11:20am
Atai drops pipeline assets, takes on debt to extend cash runway
Aug 15, 2022 7:00am
Psychedelics inch toward approval, but market may not be ready
Aug 17, 2021 10:40am
Beckley Psytech bags $80M to fuel psychedelics for depression
Aug 16, 2021 11:42am
Investors are tripping on psychedelics despite murky path ahead
Aug 16, 2021 9:50am
